Clinical Efficacy And Safety Analysis Of Veniecra Combined With HMA Drugs In Elderly Acute Myeloid Leukemia

Objective Elderly patients with acute myeloid leukemia(AML)often respond poorly to standard regimen induction therapy.and BCL-2 overexpression is associated with AML cell survival and treatment resistance.Evaluation of the efficacy and safety of Veniecra+HMA in elderly patients with acute myeloid leukemia.Methods This study selected patients with acute myeloid leukemia in the Hematology Department of The First Affiliated Hospital and Suqian Hospital to study the safety and efficacy of HMA.During the dose escalation,the patient was rapidly increased from 100mg daily to 400mg(Dose adjustment according to consensus when combined with triazoles)daily with HMA azacitidine and decitabine.azacitidine dose and administration regimen(75mg/m2.once a day with intravenous or subcutaneous courses on days 1-7)and decitabine(20mg/m2.once a day on days 1-5).Results The patients were at least 60 years old.the median age was 74 years,with 25 men and 25 women.and they were AML patients who were not eligible for intensive chemotherapy and did not receive treatment 40%were patients with a lower risk in cytogenetics.The median time of the study was 9.98months.70%of patients achieved complete response(CR)and incomplete count(CRi).CR+CRi was 69%in patients with 400mg+azacitidine.and CR+CRi was 71%in patients with venecra+decitabine.The CR+CRi rate in patients with low cytogenetic risk and medium to high risk was 80%and 60%.and the CR+CRi rate was 67%in patients aged 75 years and older.The median duration of all patients with CR+CRi was 11.3 months,and the median overall survival count was 17.5 months.More adverse events in all patients were nausea.decreased appetite,diarrhea,decreased leukocyte count.anemia,thrombocytopenia.neutropenia with fever,and no tumor lysis syndrome was observed.Conclusion In elderly AML patients,the combination of veneecra and aza or decitabine can achieve better therapeutic efficacy and good tolerance.